Introduction {#Sec1}
============

While much previous evidence documents sociodemographic variation in cancer treatment,^[@CR1]--[@CR7]^ particularly surgery with curative intent^[@CR8]--[@CR11]^ and lung cancer,^[@CR12],[@CR13]^ most studies thus far do not take into account potential confounding by stage at diagnosis. Relatively little attention has been paid to the management of patients with stage IV disease, particularly using population-based data. While for most such patients treatment will be administered with non-curative intent, variation in management can translate to substantial differences in survival. These considerations are particularly applicable to cancer sites with large proportions of patients diagnosed with stage IV disease.

In England, routine monitoring of treatment of cancer has historically not been available, particularly for radiotherapy (RT) and chemotherapy (CT). This has historically been due to limited data availability and completeness. National audit reports routinely published treatment rates for some specific cancer sites and stages; however limited statistical adjustments for sociodemographic and clinical factors were included.^[@CR14]--[@CR16]^

Treatment among patients with advanced cancers is influenced by numerous factors such as performance status (a measure of general well-being, and the ability of a cancer patient to maintain their normal daily activities), patient age, presence and severity of comorbidity, perceived benefits and side-effects of treatment and patient choice. These are largely understandable clinically as issues that influence a patient's likely tolerance to treatment, like age, though probably to a lesser extent.^[@CR1],[@CR7],[@CR17],[@CR18]^ However, recent studies have discussed the sometimes problematic assumed relationship between frailty and age, and that more sophisticated measures of frailty should be employed during treatment decisions to reduce inequalities and offer optimum treatment.^[@CR19]^ England has an increasingly robust system of data collection among patients with cancer and thus it is now possible to study variation in treatment whilst adjusting for these important factors.

Motivated by the above considerations, we aimed to describe the population level uptake and variation of treatment among patients with stage IV lung, pancreas, stomach and oesophageal cancer, with a particular hypothesis that sociodemographic factors explain some of the variation. Understanding variation in the management of these patients may provide insights into likely mechanisms leading to inequalities in survival and help develop interventions to reduce them. We focused on four cancer sites with a high proportion of stage IV cancers diagnosed, and where prior evidence indicates that use of surgery in patients with metastatic disease is rare (this was supported in our cohort of stage IV patients, with less than 5% recorded to have received surgery intended to remove the primary tumour). Thus, CT and RT are the main treatment modalities for stage IV disease, and intent was assumed to be almost universally non-curative.

Patients and Methods {#Sec2}
====================

Study population {#Sec3}
----------------

Patients diagnosed with lung (ICD-10 C34, divided into small cell (SCLC) (Supplementary Table [1](#MOESM1){ref-type="media"}) and non-small cell (NSCLC), selected as lung cases not identified as small cell), oesophagus (C15), pancreas (C25) and stomach (C16) cancer during 2013--2014 were identified from Public Health England's national cancer registration data. All patients were resident in England and aged 15--99 years at diagnosis. Patients identified through their death certificate only (18 patients) were excluded, as were patients with mis-ordered dates (13 patients), for example a date of death prior to diagnosis.

Cancer registration data, which in isolation contains some treatment data, was linked with the Radiotherapy Dataset (RTDS)^[@CR20]^ and Systemic Anti-Cancer Therapy (SACT)^[@CR21]^ data to ascertain treatment uptake for each patient from 30 days prior to and 183 days following the date of cancer diagnosis. The datasets were linked on NHS number; therefore the additional treatment-specific datasets (RTDS and SACT) were only used for patients who were diagnosed with one tumour in any 6 month period. The outcome variables were therefore RT (without CT), CT (without RT) and CTRT, which may have been delivered independently of each other. Immunotherapies are captured in SACT, and are thus included as 'CT'. Brachytherapy episodes were excluded, as were SACT records for hormonal therapy and treatment other than active anti-cancer therapy (such drug therapies for the management of bone metastasis such as zoledronic acid, pamidronate and denosumab).

To calculate the income deprivation quintile, each patient's postcode at diagnosis (at the Lower Super Output Area geography) was linked to the income domain of the Index of Multiple Deprivation 2010.^[@CR22]^ Equal population quintiles were derived over the whole of England from the income domain score, and each cancer patient was assigned the income deprivation quintile of their local geography. Ethnicity was self-reported and recorded in the hospital patient administration systems. If the patient's ethnicity was unknown in the cancer registration data, the modal value from the Hospital Episode Statistics (HES) data^[@CR23]^ was used. Ethnicity is recorded for each hospital episode, and the most common ethnicity was chosen (or the most recent of these in the event of a tied number of records). The comorbidity index was derived as per the Charlson comorbidity index lookup table^[@CR24]^ using in-patient HES data, with the same methodology as described by Maringe et al (2017),^[@CR25]^ but with a different time window: from 27 months to 3 months prior to the cancer diagnosis. Performance status was obtained from both cancer registration and SACT data, and is as recorded by the multi-disciplinary team (MDT). The performance status was measured at both diagnosis and at the start of each chemotherapy regimen, thus if a patient was assigned two performance status values, the maximum (most disadvantageous) value was chosen. Vital status was ascertained from the Office of National Statistics (ONS) mortality data.

Statistical analysis {#Sec4}
--------------------

Each individual entered the analysis at 31 days before the date of cancer diagnosis (to allow for treatment commencing prior to diagnosis date, as defined under the European Network of Cancer Registries (ENCR) rules which prioritise date of pathology^[@CR26]^) and was censored at the earliest of date of first treatment, death (from the patient's vital status), or end of the 6 months post-diagnosis follow up. 1.0% of RT events and 0.2% of CT events occurred in the 31 day period prior to ENCR cancer diagnosis date.

To account for varied survival times among the cohort, a model was chosen to account for time at risk, as defined above. Hazard rate ratios (for treatment vs. no treatment, henceforth called treatment rate ratios (TRR)) were calculated using a generalised linear model with a Poisson error structure on collapsed data^[@CR27]^ where the treatment rate in the reference population was taken as zero. This was performed using the STRS program in Stata 13.1.^[@CR27],[@CR28]^ This modelling approach for excess mortality is the analogue of the relative survival approach. Individual patient-level data was used; therefore exact survival times were available. The data was collapsed for ease of computation, as Dickman and colleagues demonstrated equivalent results to un-collapsed data.^[@CR27]^ The excess hazards are assumed to be constant throughout each month of follow-up therefore a Poisson process is assumed for the rate of first treatments per follow-up interval.^[@CR27]^ The hazard is dependent on a subset of the explanatory variables (age, sex and follow-up period). Where patients received both RT and CT, the start date of this combined treatment was considered to be the first event.

Separate regression models were performed for: RT (without CT), CT (without RT) and CTRT. The factors investigated were: cancer site, sex, age (\<50, 50--59, 60--69, 70--79, 80+), sociodemographic deprivation (income deprivation quintile: 1---least deprived, 2, 3, 4, 5---most deprived), ethnicity (white, non-white, unknown) and Charlson comorbidity index (0, 1, 2, 3+).^[@CR29]^

Supplementary analyses included performance status as an explanatory variable in the multivariable regression model (missing data precluded its use as a main explanatory variable). Due to theoretical concerns of associations of treatment modality with morphology subtypes, we also conducted additional analysis of dominant subtypes restricting the tumour cohort to oesophageal, pancreatic and stomach adenocarcinomas (ICD-O-2 morphologies 8140-8576).

Tests for heterogeneity were performed jointly across all categories of each variable, using a post-estimation Wald test. Statistical significance was defined as two-sided with a *p* \< 0.05.

Results {#Sec5}
=======

Patient characteristics {#Sec6}
-----------------------

50,232 patients with stage IV lung, oesophageal, stomach and pancreatic cancers were diagnosed during 2013--2014, and cohort characteristics for each of the cancer sites are summarised in Table [1](#MOESM1){ref-type="media"}. Across all sites, 24% received CT (without RT), 13% of patients received RT (without CT) and 11% received both CT and RT (CTRT), which varied by cancer type from 1% for CTRT and RT among patients with pancreatic cancer to 37% for CT among patients with oesophageal cancer (Table [2](#MOESM1){ref-type="media"}). The proportion of patients who died during the 6 month follow-up period varied from 57% to 78% for oesophageal and pancreatic cancer, respectively, and among these patients the median survival time varied from 41 days (pancreatic and SCLC) to 63 days (oesophageal) (Supplementary Table [2](#MOESM2){ref-type="media"}).Table 1Patient characteristics of stage IV lung, oesophageal, pancreatic and stomach cancers diagnosed in 2013--2014 in EnglandNumber of cancers diagnosedTotalNSCLC%SCLC%Oesophagus%Stomach%Pancreas%Total30,4315,0794,0233,5887,11150,232*Year of diagnosis* 201314,979492,532501,847461,783503,2884624,429 201415,452512,547502,176541,805503,8235425,803*Sex* Male16,839552,712532,898722,401673,7155228,565 Female13,592452,367471,125281,187333,3964821,667*Age at cancer diagnosis* \<50847314831754262731541,747 50--592,95310697145571436610829125,402 60--698,135271,761351,21830770211,8812613,765 70--7910,075331,771351,234311,180332,2753216,535 80+8,4212870214839211,010281,8112512,783*Charlson comorbidity index* 022,840753,922773,285822,816785,4617738,324 13,6611257811373939511845125,852 22,007733171925228643563,193 3+1,923624851734149437052,863*Deprivation quintile* 1: least deprived4,377146231273118601171,445207,777 25,516188871783221733201,531229,499 36,411211,0092085721741211,5772210,595 46,862231,1922383221769211,3491911,004 5: most deprived7,265241,3682777119744211,2091711,357*Ethnicity* White28,133924,817953,781943,198896,4119046,340 Non-white1,18241202912264737652,033 Unknown1,116414231514126432451,859*Performance status* 02,56784148586153691041864,354 1+14,985493,109611,342331,164321,1611621,761 Unknown12,879421,556312,095522,055575,5327824,117*NSCLC* non-small cell lung cancer, *SCLC* small cell lung cancerTable 2Treatment rate ratios for chemotherapy alone (CT), radiotherapy alone (RT) and chemotherapy & radiotherapy (CTRT) within 6 months of diagnosis of lung, oesophageal, pancreatic and stomach cancers in 2013--2014 from three unadjusted and three fully adjusted multivariable models with cancer site, sex, age at diagnosis, deprivation, ethnicity and Charlson comorbidity indexRTCTCTRT%^a^TRR (95% CI)%^a^TRR (95% CI)%^a^TRR (95% CI)UnadjustedFully adjustedUnadjustedFully adjustedUnadjustedFully adjusted*Sex*  Male13RefRef24RefRef11RefRef  Female120.88 (0.84, 0.92)0.85 (0.81, 0.89)230.90 (0.86, 0.93)0.97 (0.93, 1.00)121.02 (0.97, 1.08)0.95 (0.91, 1.01)  *p* for heterogeneity^b^\<0.0001\<0.0001\<0.00010.080.360.08*Age at cancer diagnosis* \<5090.57 (0.48, 0.67)0.65 (0.55, 0.77)451.35 (1.25, 1.46)1.24 (1.15, 1.34)211.11 (0.99, 1.24)1.41 (1.26, 1.58) 50--59120.86 (0.79, 0.94)0.91 (0.83, 0.99)341.04 (0.99, 1.10)1.01 (0.95, 1.06)221.27 (1.18, 1.36)1.33 (1.24, 1.43) 60--6913RefRef32RefRef17RefRef 70--79141.21 (1.14, 1.29)1.20 (1.13, 1.28)240.78 (0.75, 0.82)0.79 (0.76, 0.83)90.55 (0.51, 0.58)0.56 (0.53, 0.60) 80+121.22 (1.14, 1.30)1.13 (1.05, 1.21)70.21 (0.20, 0.23)0.22 (0.21, 0.24)20.14 (0.12, 0.15)0.15 (0.13, 0.17) *p* for heterogeneity^b^\<0.0001\<0.0001\<0.0001\<0.0001\<0.0001\<0.0001*Charlson comorbidity index* 013RefRef26RefRef13RefRef 1121.01 (0.93, 1.09)0.95 (0.88, 1.03)190.76 (0.71, 0.81)0.86 (0.81, 0.91)90.70 (0.63, 0.76)0.81 (0.74, 0.89) 2121.08 (0.98, 1.20)0.99 (0.89, 1.09)160.63 (0.58, 0.69)0.74 (0.68, 0.81)80.64 (0.56, 0.73)0.78 (0.69, 0.89) 3+121.15 (1.03, 1.28)0.98 (0.88, 1.10)110.43 (0.39, 0.48)0.57 (0.51, 0.64)40.32 (0.26, 0.38)0.41 (0.34, 0.50) *p* for heterogeneity^b^0.040.67\<0.0001\<0.0001\<0.0001\<0.0001*Deprivation quintile* 1: least deprived12RefRef27RefRef12RefRef 2121.04 (0.96, 1.13)1.02 (0.94, 1.11)250.95 (0.90, 1.01)0.95 (0.90, 1.01)121.04 (0.95, 1.14)0.96 (0.88, 1.04) 3131.12 (1.03, 1.22)1.09 (1.00, 1.18)230.88 (0.83, 0.93)0.89 (0.84, 0.94)111.01 (0.93, 1.10)0.90 (0.82, 0.98) 4131.09 (1.00, 1.18)1.04 (0.96, 1.13)230.86 (0.81, 0.92)0.86 (0.81, 0.91)111.04 (0.96, 1.14)0.84 (0.77, 0.91) 5: most deprived131.14 (1.05, 1.23)1.08 (1.00, 1.18)220.85 (0.80, 0.90)0.82 (0.78, 0.87)111.07 (0.98, 1.17)0.78 (0.71, 0.85) *p* for heterogeneity^b^0.010.18\<0.0001\<0.00010.48\<0.0001*Ethnicity* White13RefRef24RefRef11RefRef Non-white120.85 (0.75, 0.96)0.91 (0.80, 1.04)291.13 (1.04, 1.22)1.01 (0.92, 1.10)141.07 (0.95, 1.21)1.07 (0.95, 1.21) Unknown110.93 (0.81, 1.08)0.93 (0.81, 1.07)170.80 (0.71, 0.89)0.75 (0.67, 0.84)70.67 (0.56, 0.79)0.67 (0.56, 0.79) *p* for heterogeneity^b^0.030.24\<0.0001\<0.0001\<0.0001\<0.0001*Cancer site* NSCLC18RefRef18RefRef12RefRef SCLC50.25 (0.22, 0.29)0.26 (0.23, 0.29)331.89 (1.79, 1.99)1.61 (1.52, 1.70)323.31 (3.12, 3.51)2.91 (2.74, 3.09) Oesophagus100.47 (0.43, 0.52)0.47 (0.42, 0.52)372.04 (1.92, 2.16)1.88 (1.77, 1.99)80.57 (0.51, 0.64)0.47 (0.42, 0.53) Stomach50.25 (0.21, 0.29)0.25 (0.21, 0.29)362.14 (2.02, 2.28)2.16 (2.03, 2.30)40.26 (0.21, 0.31)0.23 (0.19, 0.27) Pancreas10.08 (0.07, 0.10)0.09 (0.07, 0.10)271.86 (1.76, 1.96)1.78 (1.68, 1.87)10.12 (0.10, 0.15)0.10 (0.09, 0.13) *p* for heterogeneity^b^\<0.0001\<0.0001\<0.0001\<0.0001\<0.0001\<0.0001CI confidence interval, *NSCLC* non-small cell lung cancer, *SCLC* small cell lung cancer, *TRR* treatment rate ratio.^a^ Proportion of patients recorded to receive treatment in each category.^b^ Performed jointly across all categories of each variable, using a post-estimation Wald test

Overall variation in treatment usage {#Sec7}
------------------------------------

Treatment rates varied significantly across cancer sites (*p* \< 0.0001). RT was used more frequently in patients with NSCLC, CT in patients with stomach cancer and CTRT in patients with SCLC (Table [2](#MOESM1){ref-type="media"}). Full adjustment attenuated crude TRR values up to 33% (Table [2](#MOESM1){ref-type="media"}), therefore, only adjusted results are presented in Table [3](#MOESM1){ref-type="media"} onwards. Across all cancer sites, there was a significant association between female sex and lower rate of RT (*p* \< 0.0001), but there was no evidence for association by sex for CT or CTRT use (*p* = 0.08 for both). The sex gradient in RT use among NSCLC was driven by non-squamous tumours (Supplementary Table [3](#MOESM3){ref-type="media"}). There was no difference in treatment use by known ethnicity. Analyses of radiotherapy and chemotherapy independently of the other treatment found no substantive differences, except for an association between increasing age at diagnosis and decreasing use of radiotherapy (Supplementary Table [4](#MOESM4){ref-type="media"}). Restriction to upper gastrointestinal adenocarcinomas (Supplementary Table [5](#MOESM5){ref-type="media"}) demonstrated highly concordant patterns of variation with that observed for results of all morphologies combined for upper gastrointestinal cancers (Table [2](#MOESM1){ref-type="media"}), with an expected loss of significance due to diminished sample size among stratified results (data not shown).Table 3Treatment rate ratios for radiotherapy alone (RT) within 6 months of diagnosis of lung, oesophageal, pancreatic and stomach cancers in 2013--2014, from a fully adjusted multivariable model with sex, age at diagnosis deprivation, ethnicity and Charlson comorbidity index, stratified by cancer siteNSCLCSCLCOesophagusStomachPancreas%^a^TRR (95% CI)%^a^TRR (95% CI)%^a^TRR (95% CI)%^a^TRR (95% CI)%^a^TRR (95% CI)*Sex*  Male19Ref6Ref9Ref5Ref1Ref  Female160.82 (0.77, 0.86)50.85 (0.67, 1.09)141.41 (1.15, 1.74)50.87 (0.63, 1.19)11.03 (0.69, 1.52)  *p* for heterogeneity^b^\<0.00010.190.0010.390.89*Age at cancer diagnosis*  \<50150.69 (0.57, 0.83)10.35 (0.09, 1.43)70.63 (0.34, 1.18)10.31 (0.09, 1.03)10.65 (0.23, 1.86)  50--59190.93 (0.84, 1.03)41.14 (0.73, 1.77)60.64 (0.43, 0.94)40.99 (0.51, 1.92)10.76 (0.38, 1.51)  60--6919Ref4Ref9Ref4Ref2Ref  70--79191.13 (1.06, 1.21)61.76 (1.28, 2.40)121.34 (1.04, 1.72)61.80 (1.15, 2.80)21.03 (0.63, 1.66)  80+150.96 (0.89, 1.04)103.58 (2.54, 5.05)141.86 (1.42, 2.44)72.56 (1.64, 4.00)10.82 (0.46, 1.45)  *p* for heterogeneity^b^\<0.0001\<0.0001\<0.0001\<0.00010.78*Charlson comorbidity index*  018Ref5Ref10Ref5Ref1Ref  1160.93 (0.85, 1.01)50.95 (0.64, 1.42)90.89 (0.63, 1.26)71.48 (0.99, 2.22)21.64 (0.97, 2.76)  2160.94 (0.84, 1.05)71.43 (0.93, 2.19)131.14 (0.74, 1.74)71.32 (0.77, 2.26)10.79 (0.29, 2.16)  3+150.92 (0.82, 1.04)101.80 (1.17, 2.77)100.97 (0.60, 1.56)71.27 (0.66, 2.42)21.55 (0.67, 3.59)  *p* for heterogeneity^b^0.190.020.830.230.20*Deprivation quintile*  1: least deprived18Ref5Ref11Ref5Ref2Ref  2181.01 (0.92, 1.11)71.30 (0.85, 1.99)111.07 (0.79, 1.45)61.11 (0.71, 1.74)10.72 (0.40, 1.28)  3181.10 (1.01, 1.21)51.02 (0.66, 1.57)111.03 (0.76, 1.39)61.01 (0.63, 1.60)20.87 (0.51, 1.51)  4171.05 (0.96, 1.15)51.15 (0.75, 1.74)100.96 (0.71, 1.32)50.92 (0.58, 1.48)10.65 (0.34, 1.22)  5: most deprived181.11 (1.02, 1.21)40.97 (0.63, 1.47)90.87 (0.63, 1.21)40.66 (0.39, 1.11)10.67 (0.35, 1.29)  *p* for heterogeneity^b^0.050.490.770.310.58*Ethnicity*  White18Ref5Ref10Ref5Ref1Ref  Non-white180.86 (0.75, 1.00)81.32 (0.68, 2.59)121.24 (0.68, 2.28)61.68 (0.99, 2.86)21.19 (0.51, 2.78)  Unknown150.89 (0.76, 1.04)81.82 (0.99, 3.35)50.52 (0.26, 1.05)51.22 (0.54, 2.77)21.66 (0.72, 3.82)  *p* for heterogeneity^b^0.050.120.140.150.46CI confidence interval, *NSCLC* non-small cell lung cancer, *SCLC* small cell lung cancer, *TRR* treatment rate ratio.^a^ Proportion of patients recorded to receive treatment in each category.^b^ Performed jointly across all categories of each variable, using a post-estimation Wald test

Variation by age at cancer diagnosis {#Sec8}
------------------------------------

For all cancer sites (except pancreas, *p* = 0.78) there was a positive association between older age and higher RT rate (*p* \< 0.0001; Table [3](#MOESM1){ref-type="media"}). The steepest association was for SCLC (TRR: 0.35 (95% CI 0.09, 1.43) for ages \<50 to 3.58 (95% CI 2.54, 5.05) for ages 80+). There was very strong statistical evidence for associations between increasing age and lower CTRT use for all sites (*p* \< 0.0001; Table [4](#MOESM1){ref-type="media"}), this association being steeper for pancreatic cancer, with TRRs ranging from 1.77 (95% CI 0.86, 3.63) for ages \<50 to 0.28 (95% CI 0.12, 0.68) for ages 80+. Older age was associated with a lower rate of CT (*p* \< 0.0001; Table [5](#MOESM1){ref-type="media"}), except for SCLC, with the highest use in patients aged 70--79 (TRR: 1.26 (95% CI 1.13, 1.41)).Table 4Treatment rate ratios for chemotherapy & radiotherapy (CTRT) within 6 months of diagnosis of lung, oesophageal, pancreatic and stomach cancers in 2013--2014, from a fully adjusted multivariable model with sex, age at diagnosis, deprivation, ethnicity and Charlson comorbidity index, stratified by cancer siteNSCLCSCLCOesophagusStomachPancreas%^a^TRR (95% CI)%^a^TRR (95% CI)%^a^TRR (95% CI)%^a^TRR (95% CI)%^a^TRR (95% CI)*Sex*  Male12Ref31Ref9Ref4Ref1Ref  Female120.96 (0.90, 1.03)331.00 (0.90, 1.10)60.82 (0.63, 1.07)30.63 (0.42, 0.95)11.06 (0.71, 1.57)  *p* for heterogeneity^b^0.220.930.150.030.79*Age at cancer diagnosis*  \<50291.52 (1.33, 1.74)501.31 (1.03, 1.66)100.87 (0.52, 1.44)91.69 (1.00, 2.85)31.77 (0.86, 3.63)  50 -- 59251.36 (1.25, 1.49)471.26 (1.10, 1.43)141.37 (1.03, 1.82)51.04 (0.60, 1.78)32.07 (1.24, 3.48)  60 -- 6918Ref39Ref10Ref5Ref2Ref  70 -- 7990.53 (0.49, 0.58)250.59 (0.53, 0.67)70.75 (0.57, 0.98)30.56 (0.35, 0.88)10.77 (0.45, 1.32)  80+20.11 (0.10, 0.13)110.28 (0.22, 0.35)20.24 (0.14, 0.40)10.26 (0.13, 0.51)00.28 (0.12, 0.68)  *p* for heterogeneity^b^\<0.0001\<0.0001\<0.0001\<0.0001\<0.0001*Charlson comorbidity index*  013Ref34Ref9Ref4Ref2Ref  180.73 (0.65, 0.83)280.88 (0.75, 1.04)91.27 (0.88, 1.83)30.93 (0.50, 1.74)21.19 (0.66, 2.14)  270.71 (0.60, 0.84)270.92 (0.74, 1.14)50.76 (0.41, 1.44)31.06 (0.49, 2.30)10.66 (0.21, 2.11)  3+30.35 (0.27, 0.45)150.50 (0.36, 0.70)40.71 (0.33, 1.51)20.80 (0.25, 2.55)00.27 (0.04, 1.92)  *p* for heterogeneity^b^\<0.00010.00040.330.980.45*Deprivation quintile*  1: least deprived13Ref32Ref11Ref4Ref2Ref  2130.98 (0.88, 1.10)320.91 (0.76, 1.09)90.86 (0.63, 1.19)30.93 (0.52, 1.66)21.00 (0.56, 1.77)  3110.86 (0.77, 0.96)351.03 (0.87, 1.23)70.70 (0.50, 0.98)41.16 (0.67, 2.01)10.71 (0.38, 1.33)  4110.82 (0.74, 0.92)310.87 (0.73, 1.03)80.71 (0.51, 0.99)40.96 (0.55, 1.69)11.00 (0.55, 1.82)  5: most deprived110.77 (0.69, 0.85)300.81 (0.68, 0.96)70.61 (0.43, 0.87)30.90 (0.50, 1.62)10.84 (0.44, 1.63)  *p* for heterogeneity^b^\<0.00010.0090.040.910.79Ethnicity  White12Ref32Ref8Ref4Ref1Ref  Non-white181.16 (1.01, 1.33)310.83 (0.59, 1.15)101.24 (0.64, 2.43)51.08 (0.59, 1.97)10.39 (0.12, 1.26)  Unknown80.67 (0.55, 0.83)210.73 (0.51, 1.05)30.39 (0.16, 0.95)20.53 (0.13, 2.16)10.46 (0.11, 1.88)  *p* for heterogeneity^b^0.00010.130.090.650.17CI confidence interval, *NSCLC* non-small cell lung cancer, *SCLC* small cell lung cancer, *TRR* treatment rate ratio.^a^ Proportion of patients recorded to receive treatment in each category.^b^ Performed jointly across all categories of each variable, using a post-estimation Wald testTable 5Treatment rate ratios for chemotherapy alone (CT) within 6 months of diagnosis of lung, oesophageal, pancreatic and stomach cancers in 2013--2014, from a fully adjusted multivariable model with sex, age at diagnosis, deprivation, ethnicity and Charlson comorbidity index, stratified by cancer siteNSCLCSCLCOesophagusStomachPancreas%^a^TRR (95% CI)%^a^TRR (95% CI)%^a^TRR (95% CI)%^a^TRR (95% CI)%^a^TRR (95% CI)*Sex*  Male18Ref33Ref40Ref36Ref28Ref  Female191.02 (0.97, 1.08)330.98 (0.89, 1.08)290.84 (0.74, 0.95)340.98 (0.87, 1.11)250.97 (0.88, 1.06)  *p* for heterogeneity^b^0.390.740.0070.780.48*Age at cancer diagnosis*  \<50331.18 (1.04, 1.34)360.96 (0.72, 1.26)611.32 (1.08, 1.63)611.17 (0.97, 1.41)561.51 (1.28, 1.78)  50--59281.03 (0.95, 1.12)300.79 (0.67, 0.92)521.07 (0.93, 1.24)541.06 (0.89, 1.26)421.10 (0.97, 1.25)  60--6926Ref35Ref48Ref53Ref38Ref  70--79190.78 (0.73, 0.83)381.26 (1.13, 1.41)350.73 (0.64, 0.82)360.62 (0.54, 0.71)250.68 (0.61, 0.76)  80+50.21 (0.19, 0.23)220.82 (0.69, 0.98)80.16 (0.12, 0.20)100.16 (0.13, 0.20)50.15 (0.12, 0.19)  *p* for heterogeneity^b^\<0.0001\<0.0001\<0.0001\<0.0001\<0.0001*Charlson comorbidity index*  020Ref34Ref40Ref38Ref29Ref  1140.84 (0.77, 0.92)330.97 (0.83, 1.13)270.76 (0.62, 0.93)310.92 (0.76, 1.12)230.85 (0.73, 0.98)  2120.72 (0.63, 0.82)290.84 (0.69, 1.04)220.64 (0.47, 0.86)260.75 (0.57, 0.98)180.76 (0.60, 0.96)  3+70.49 (0.41, 0.58)321.06 (0.84, 1.33)140.43 (0.28, 0.64)150.53 (0.35, 0.80)120.54 (0.40, 0.73)  *p* for heterogeneity^b^\<0.00010.39\<0.00010.004\<0.0001*Deprivation quintile*  1: least deprived21Ref32Ref40Ref38Ref30Ref  2190.92 (0.84, 1.01)331.05 (0.87, 1.25)350.85 (0.72, 1.00)381.04 (0.88, 1.24)290.99 (0.87, 1.13)  3170.85 (0.77, 0.92)320.97 (0.82, 1.16)370.92 (0.79, 1.08)360.98 (0.82, 1.18)270.92 (0.80, 1.05)  4170.81 (0.75, 0.89)341.10 (0.92, 1.30)370.90 (0.76, 1.05)340.87 (0.72, 1.03)240.82 (0.71, 0.95)  5: most deprived170.77 (0.71, 0.84)351.16 (0.98, 1.37)340.77 (0.65, 0.91)320.81 (0.68, 0.98)240.78 (0.67, 0.91)  *p* for heterogeneity^b^\<0.00010.130.030.020.002*Ethnicity*  White18Ref34Ref37Ref36Ref27Ref  Non-white251.10 (0.97, 1.24)320.90 (0.65, 1.25)411.17 (0.84, 1.63)380.80 (0.65, 0.99)310.96 (0.79, 1.17)  Unknown140.79 (0.67, 0.92)250.83 (0.59, 1.16)361.04 (0.79, 1.36)210.59 (0.40, 0.87)130.48 (0.35, 0.65)  *p* for heterogeneity^b^0.0030.450.620.004\<0.0001CI confidence interval, *NSCLC* non-small cell lung cancer, *SCLC* small cell lung cancer, *TRR* treatment rate ratio.^a^ Proportion of patients recorded to receive treatment in each category^b^ Performed jointly across all categories of each variable, using a post-estimation Wald test

Variation by deprivation {#Sec9}
------------------------

Mostly, increasing deprivation quintile was associated with decreasing use of CT and CTRT (Tables [4](#MOESM1){ref-type="media"} and [5](#MOESM1){ref-type="media"}). The steepest association was oesophageal cancer, as the TRR among patients in the most deprived quintile was 0.77 (95% CI 0.65, 0.91) for CT and 0.61 (95% CI 0.43, 0.87) for CTRT. Exceptions with no association were SCLC for CT, and stomach and pancreas for CTRT. There was no evidence of an association of deprivation with RT (*p* = 0.18; Table [2](#MOESM1){ref-type="media"}).

Variation by Charlson comorbidity index {#Sec10}
---------------------------------------

Increasing comorbidity index was associated with decreasing CT and CTRT rates (*p* \< 0.0001; Table [2](#MOESM1){ref-type="media"}). The steepest association was for NSCLC and CTRT (the TRR among patients with a comorbidity index of 3+ was 0.35 (95% CI 0.27, 0.45)) (Table 4). The exceptions with no significant association were SCLC and CT (Table 5), and oesophagus, stomach and pancreas and CTRT (Table 4). For most sites, no association was found between comorbidity and RT, except for a positive association with SCLC (*p* = 0.02) of 1.80 (95% CI 1.17, 2.77) among patients with a comorbidity index of 3+ (Table [3](#MOESM1){ref-type="media"}).

Association with performance status {#Sec11}
-----------------------------------

Performance status (PS) was known for 52% of the cohort. Inclusion of PS made no substantive difference to the overall associations (Supplementary Table [6](#MOESM6){ref-type="media"}). However, there was a significant association with PS for all treatments (*p* \< 0.0001). In stratified analysis (by broader PS groups), for example, no association was found between CTRT and comorbidity nor deprivation among patients with a PS of 0 (*p* = 0.62 and *p* = 0.47, respectively; Supplementary Table [7](#MOESM7){ref-type="media"}).

DISCUSSION {#Sec12}
==========

Our population-based study of patients with stage IV lung, oesophageal, stomach and pancreatic cancer aimed to define uptake and variation in treatment use. The main finding was significant variation in the rates of CT and RT, for patients who receive one treatment alone or both within 6 months post diagnosis. As expected on clinical grounds, there was significant heterogeneity by cancer type, given the variable efficacy of different treatment modalities in different cancers. After accounting for this, variation was largely driven by age at cancer diagnosis, but non-trivial associations with comorbidity and deprivation were also observed, and additionally associations of sex with RT use. More variation in treatment appeared to align to where clinical guidelines are less clear. One example of this was the differential (by sex) use of RT among patients with non-squamous NSCLC tumours, where the indication for use of RT is less clear. Stratification by performance status demonstrated non-trivial adjustments to these associations suggesting that improved completeness of performance status may further explain variation in treatment, particularly as patients with unknown performance status appeared to have poor health status.

Over half of patients received neither CT nor RT within 6 months following diagnosis, although a significant fraction died quickly after diagnosis. Our study focused on RT and/or CT use, though these patients may have received other treatments, appropriately not been offered treatment on clinical grounds, received treatment in a private setting or chosen not to be treated. A small proportion of patients (estimates vary, but a recent study in London found 0.6% of breast cancer patients had been treated privately and did not appear in the cancer registration data^[@CR30]^) are believed to be treated in the private setting, and as they are treated using standard clinical guidelines the incompleteness of this data is unlikely to impact the findings of this study. It is also possible that a limitation in data completeness has contributed to missing a fraction of the treatments.

Variation in treatment rate by age at diagnosis and Charlson comorbidity index {#Sec13}
------------------------------------------------------------------------------

We found large gradients in treatment use among patients with stage IV cancer for both CT and RT with increasing age, and non-trivial associations with increasing level of comorbidity. Such variations may be expected, as clinicians and patients must balance the benefit of palliative therapy against the toxicity of treatment.^[@CR17]^ CT can be highly toxic in patients with multiple comorbidities, which is supported by our findings of reduced usage among those with more comorbidity. Palliative RT for advanced disease typically has a very low rate of side effects therefore would be expected to be very much less influenced by the presence of comorbidities. Our findings support this and are largely consistent with a study of non-surgically treated lung cancer patients.^[@CR1]^ Despite clinical appropriateness in certain circumstances, under-treatment of elderly patients has been well-documented for a number of years;^[@CR18]^ which may partly explain why in international comparisons of death rates the number of excess deaths in England are highest among older patients with cancer.^[@CR31]--[@CR35]^ Treatment rates of advanced disease do appear to be higher in the US for some cancer sites, although evidence is limited.^[@CR36]^ In the United Kingdom, however, there has been shown to be an increasing use of chemotherapy for advanced NSCLC patients with low performance status;^[@CR15]^ therefore, the discrepancy with the US study may be reducing. However, more treatment is not universally preferred, and there are circumstances where treatment may be more harmful, due to the health status of the patient and the potential impact of the side effects of treatment. Understanding the impact of variation on survival should provide further evidence for this.

The different treatment rates among older, compared to younger, patients were not explained by the presence of comorbidity, poor performance status or other demographic factors. Our study demonstrated positive associations between the likelihood of RT use and increasing age at diagnosis, and a negative association with the likelihood of CT and CTRT use. The association between increasing age at diagnosis and lower CT use concords with prior US literature.^[@CR7],[@CR37]^ The association between increasing age and increasing RT, however, was in contrast to a recent Danish study,^[@CR1]^ which is likely due to differences in stage distribution of the selected populations. In adjusted analysis, increasing RT use with increasing age was only observed among patients not treated by CT. This presumably reflects that RT is better tolerated among some elderly patients than CT.

Variation in treatment rate by deprivation {#Sec14}
------------------------------------------

A significant association with deprivation was demonstrated for patients treated with CT alone, and for patients treated with both CT and RT within 6 months but no association was found for RT. This was largely driven by patients with lung or oesophageal cancers. However, the association with CT alone was not apparent for SCLC patients, though we were unable to identify a clinical explanation for this. The deprivation deficit has been documented in previous studies of oesophagogastric cancer^[@CR38]^ and lung cancer.^[@CR13],[@CR39],[@CR40]^ Our work found the greatest association for CT. This confirms findings from a systematic review and meta-analysis of lung cancer treatment, which found a significant negative association between socioeconomic position and chemotherapy receipt, but no association with radiotherapy receipt.^[@CR41]^ However, other published studies in England, which have accounted for travel time, have documented a more pronounced deprivation deficit in RT compared to CT treatment.^[@CR42],[@CR43]^ This was largely attributed to travel times to RT centres. These local delivery issues may have reduced impact within a national study such as ours, and differences in the number of hospital attendances for palliative radiotherapy and chemotherapy delivery as compared to curative delivery may explain this discrepancy.

Strengths and limitations {#Sec15}
-------------------------

This study has population-based coverage, possible because of access to a wide range of routinely collected health care data in England. The availability of linked treatment datasets improved treatment ascertainment for multiple cancer types. There is now a high level of staging completeness which has allowed the reliable identification of a group of late stage cancer patients at a national level.^[@CR44]^

Many patients with very advanced, stage IV cancers die very quickly following diagnosis and one strength of our methodology is that these patients, who would be very highly unlikely to receive treatment, have been censored. This allowed the estimates to be calculated using a patient's time available for treatment therefore producing accurate estimates of the treatment rates and associations.

The main limitation of this study is that patient choice could not be accounted for. Inclusion of this information may attenuate or even help explain the associations with deprivation and age. Patient choice is influenced by many factors,^[@CR45]^ and there is limited population-based data reporting patient choice. More deprived patients may be less inclined to accept the associated risks of treatment, the patient--clinician interaction may be impacted and understanding of the disease may differ,^[@CR46]--[@CR48]^ and there may be increased fatalism. Having adjusted for co-morbidities and, to a lesser extent, performance status, it seems unlikely that underlying ill-health is the only factor explaining the lower treatment rates in more socially deprived patients. Specifically, the differential impact of deprivation on the choice of active treatment was less apparent among those patients with a better performance status. However, we were not able to fully take account of frailty,^[@CR19]^ smoking status or lung function, factors which are particularly relevant for lung cancer, though less so in the palliative setting. As always in population-based studies, there are also some limitations relating to data completeness, in particular incomplete data on performance status and the fact that our index of comorbidity is based only on in-patient hospital records. More complete performance status may have explained some of the remaining variation, particularly among the gastrointestinal cancers where completeness was the lowest. It is also worth noting that for oesophageal, pancreatic and stomach cancer, the staging data completeness increased markedly from 2013 to 2014, thus increasing the number of stage IV diagnoses in 2014 (Supplementary Table [8](#MOESM8){ref-type="media"}).

Further research {#Sec16}
----------------

This study has clearly demonstrated that unexplained variation in receipt of treatment exists among a cohort of stage IV cancer patients in England. However, it is not clear if this variation results in differences in expected survival for these patients. Statistical analyses may permit understanding of the excess mortality among these patients, and the attribution of any excess mortality to known patient and tumour characteristics, as in a study of short-term breast cancer mortality.^[@CR49]^ This is vital further research among these patients diagnosed with stage IV disease. This information also requires further work to define why some patients, particularly the elderly, are not treated with either radiotherapy or chemotherapy, as barriers to patients receiving palliative treatment can often be overcome.^[@CR50]^ This is an active area of research among patients with various cancer types in older patients.^[@CR51],[@CR52]^

Implications for policy and practice {#Sec17}
------------------------------------

The main finding is that older patients are, in general, receiving lower rates of active treatment for their cancers and that these low rates cannot be fully explained by co-morbidity. It is well known that there are higher excess death rates from a number of cancers in older patients in England than in some other countries. The explanation for this warrants further work and may well be largely related to patient choice influenced by cultural factors. Healthcare providers need to examine how they support older patients when making treatment decisions and policy makers need to improve the access of cancer teams to such tools as the Comprehensive Geriatric Assessment.^[@CR50]--[@CR52]^ Qualitative studies and ethnography are needed to understand the patient-clinician interaction, and its impact on patient choice of treatment. Data linkages to primary care information should be explored, to capture unmeasured morbidity which may explain the variation in treatment received among these patients.

Conclusion {#Sec18}
==========

Contributing to a body of evidence documenting age and deprivation deficits in treatment for cancer patients, our study defines these deficits as being very evident among patients with advanced disease requiring essentially palliative treatments. Factors other than health status appear to be important in explaining this, as they remain after adjustment for recorded factors. Clinicians and service planners should consider these findings and future health policies should attempt to address them. Strategies should be developed to improve valid routine collection, processing and analysis of information on patient choice, to attempt to further understand this complex topic. Finally, our approach using routinely collected health data can potentially be used for routine surveillance across all cancer types, particularly for those cancers not currently covered by National Audit initiatives, thus to monitor trends in variation over time and improve outcomes for patients.
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